Currently priced at approximately $80.53 per share, Haemonetics (HAE) is trading roughly 7.6% below its 52-week ...
Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...
Zacks Investment Research on MSN
Here's why Haemonetics (HAE) is a strong growth stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Lee Hae-in Overcomes Suspension, Secures Olympic Berth After four-month ban reduction, skater clinches second place in ...
Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.
(RTTNews) - In July 2025, this pharmaceutical company started its new phase of growth as a commercial entity, following the landmark approval of the first and only oral on-demand treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback